Abbott isn't bidding for Pfizer's nutritionals unit; NantWorks plans $85.5M, 234-job plant in Indiana;

@FiercePharma: Teva eyes M&A in Asia. Future generics growth will be centered there, CFO says at #JPM12--Bloomberg. News | Follow @FiercePharma

> Abbott Laboratories ($ABT) isn't in the running to buy Pfizer's ($PFE) nutritionals business, a spokeswoman for the company told Bloomberg. News

> Injectables maker NantWorks plans to spend $85.5 million on a new manufacturing facility at Pfizer's former Exubera manufacturing site in Indiana, creating more than 230 jobs in the process. Report

> The Obama administration is likely to block the proposed $716 million merger between Omnicare and PharMerica, sources tell the New York Post. Story

> India chalked up its first year without a new case of polio, the Gates Foundation said. Item

> Novartis ($NVS) board member Pierre Landolt sold 1.41 million shares in the company, a source told Bilanz. Article

> Leo Pharma introduced a patient education and co-pay discount program for its Taclonex psoriasis-fighting products. Release

> Prescriptions for the narcotic painkiller oxycodone increased 82% from 2007 to 2010 in New York state, a new report found. More

> On the heels of new FDA restrictions on antibiotics in livestock, a global animal health organization called for action against abuse of antibiotics in agriculture. Piece

Biotech News

@FierceBiotech: Geron brings in broker to sell stem cell project. CEO thinks resources of biotech cos. at #JPM12 are 'very finite.' Article | Follow @FierceBiotech

@JohnCFierce: Unusually harsh lead on Dow Jones piece re Scangos and Biogen's "decimated" early pipeline. Is the honeymoon over? News | Follow @JohnCFierce

@RyanMFierce Optimer ($OPTR) COO is leaving antibiotics developer to "pursue other interests." Release | Follow @RyanMFierce

> BioCity Scotland creates a new life sciences incubator at Merck site. Item

> Biogen CEO Scangos aims to patch weak points in pipeline. Report

> Geron brings in broker to sell stem cell project. Story

Manufacturing News

> Interview: M+W on lean plants and carmakers. News

> FDA seeks electronic reporting of drug stability tests. Article

> It's 'T' time for contract manufacturers. Report

Vaccines News

> ImmunoCellular starts Phase II trial of brain cancer vaccine. Item

> As India nears polio eradication, researchers ponder new vaccines. News

> Microtest to manufacture ImmusanT's celiac vaccine. Story

And Finally... Running a marathon or half-marathon doesn't boost the risk of suffering a heart attack more than other vigorous exercise does, a New England Journal of Medicine study has found. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.